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1  Supporting Methods 
1.1 Strains, media, and growth conditions  
The fungal strains used in this study are listed in Table S3. Unless otherwise noted, all strains were grown 
at 30 °C on glucose minimal medium (GMM[1]) and, when appropriate, were supplemented with 0.56 g uracil 
L-1, 1.26 g uridine L-1, 1.0 g arginine L-1 and maintained as glycerol stocks at -80 ºC. Escherichia coli strain 
DH5α was propagated in LB medium with appropriate antibiotics for plasmid DNA. 
1.2 Gene cloning, plasmid construction, and genetic manipulations  
(a) A. fumigatus GliP truncation and complement strains: The gliP CTT3 or T3 domain deletion strain (TJW139 
or TJW140 respectively) was created in strain Af293.1 by replacing the CTT3 or T3 domain with A. fumigatus 
pyrG using modified double joint PCR[2] consisting of the following: 1 kb DNA fragment upstream of the CTT3 
or T3 domain, a 1.9 kb DNA fragment of A. fumigatus pyrG with glutathione gene terminator (primers 
glutapyrGF and glutapyrGR),[1,3] and a 1 kb DNA fragment downstream of the CTT3 or T3 domain. 30 μL of 
Sephadex® G-50 purified third round PCR product was used for fungal transformation. Polyethylene glycol 
based fungal transformation was done as previously described.[2,4] CTT3 or T3 domain deletants were 
confirmed by PCR and Southern blot (Figure S11a) and the correct transformants, TJW139.30 and 
TJW140.16, were used for subsequent analysis.  
For CTT3 complementation, pJW162 was created by inserting a 3.6 kb PCR product with gpdA promoter 
using the primer pair gliPgpdF/CTglipR and cloning the subsequent product into BamHI/HindIII sites of 
pUCH2-8.[5] This plasmid was used to transform TJW139.30 to complement a deletion of CTT3. The 
resulting strain was called TJW178 and was confirmed by PCR and Southern blotting (Figure S11b). All 
fungal strains used in this study are listed in Table S3, and primers are listed in Table S4. 
(b) A. fumigatus GliP point mutation: To introduce the histidine-to-alanine amino acid substitution in A. 
fumigatus, we first fully deleted gliP in a strain with a deleted akuA gene (TFYL44.1) to increase the rate of 
homologous recombination and decrease the amount of transformants that need to be screened to obtain 
the desired strain. The open reading frame of gliP was replaced with a copy of pyrG from A. parasiticus to 
complement the pyrG auxotrophy. To generate a construct to delete gliP, the flanking regions of the gliP 
open reading frame were amplified (gliP3’-F & gliP3’ R, and gliP5’-F & gliP5’-R) as well as the A. parasiticus 
pyrG gene (Ap-pyrGF & Ap-pyrGR). These PCR products were fused using double joint PCR and used to 
transform TFYL44.1 to create strain TBTP12.02 which was confirmed by Southern blot analysis (Figure 
S12).[6] Two plasmids were then generated, one which included a full length copy of gliP (pBTP12), and one 
that contained a H1754A copy of gliP (pBTP13), both targeted to the akuA locus. The pBTP12 plasmid was 
assembled by amplifying akuA flanks (KU5’-F & KU5’-R, and KU3’-F & KU 3’-R), gliP (gliP-F & gliP-R), and 
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A. fumigatus argB as the selectable marker (AFU argB fwd & AFU argB rev). These PCR fragments were 
combined with a plasmid backbone amplified from a yeast shuttle vector (YS F/YS R) in a yeast 
transformation to allow for homologous recombination to assemble the fragments into a full plasmid. pBTP13 
was assembled using the same fragments and method, except that the H1754A substitution was introduced 
by using primers containing the mutation and amplifying gliP in two separate PCR reactions (gliP-F & gliP-
H1754A-R, and gliP-H1754A-F & gliP-R). TBTP12.02 was then transformed with pBTP12 and pBTP13 to 
generate TBTP99 and TBTP100 respectively, which were confirmed by Southern blot analysis (Figure S13). 
TBTP12.02 was taken to prototrophy by amplifying argB (AFU argB fwd &AFU argB rev2) from A. fumigatus 
and selecting prototrophic transformants generating TBTP94. 
(c) Heterologous gliP expression vectors: pET24b GliP was a gift from Robert A. Cramer, Jr. (Durham, NC), 
which was constructed as described.[7] Truncations were made by PCR and reinstalled into pET24b with the 
previously utilized NdeI/XhoI restriction sites. All gliP mutants were constructed by applying PCR site-
directed mutagenesis on the original pET24 gliP as template using primers listed in Table S4. Competent 
E. coli NEB® 5-alpha (New England Biolabs) was transformed with the PCR reactions, which were 
sequenced to confirm accurate amplification. 
(d) A. fumigatus GliP point mutation at amino acid 2095 (ser->ala) : To replace serine (TCG) to alanine 
(GCG) at 2095 amino acid position, we first created a single point mutation (T→G) using jont PCR. This 
mutated template was fused to a 1.9 kb DNA fragment of A. fumigatus pyrG with glutathione gene terminator 
(primers DgPT5‘F and DgPCT3R) by joint PCR[1,3]. The fused 3kb PCR amplicon with the point mutation 
was used for transformation to Af293.1. Transformants were confirmed by Southern blotting (Figure S14) 
and sequeincing (data not shown) to obtain TJW201.38 for the subsequent experiments. 
 
1.3 Nucleic acid analysis  
Plasmid preparation, digestion with restriction enzyme, gel electrophoresis, blotting, hybridization, and probe 
preparation were performed by standard methods.[8] Aspergillus DNA for diagnostic PCR was isolated using 
the previously described method.[9] Sequence data were analyzed using the LASERGENE software package 
from DNASTAR.  
 
1.4 Northern analysis 
 Strains were grown in liquid GMM at a concentration of 1.0x106 spores per milliliter shaking at 225 rpm at 
30 ºC for 24 hours, then 25 ºC for an additional 48 h or after 24 Gliotoxin (1), was added at 25 µg/mL followed 
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by an additional 24 h of cultivation. Mycelia were harvested by filtering through Miracloth (CalBioChem), 
lyophilized, and total RNA was then isolated using Trizol (Invitrogen). The probe for gliG was prepared by 




1.5 Fermentation and metabolome extraction 
A. fumigatus strains were inoculated (1.0106 spores/mL) into 25 mL GMM in 125 mL Erlenmeyer flasks at 
30 C with shaking at 220 rpm. After 5 days, liquid fungal cultures including fungal tissue and media were 
frozen using a dry ice-acetone bath and lyophilized. The lyophilized residues were extracted with 12.5 mL 
of a mixture of acetonitrile, ethyl acetate, and water (80:15:5) for 0.5 h with vigorously stirring. Extracts were 
filtered over cotton, evaporated to dryness, and stored in 8 mL vials. Crude extracts were suspended in 1.0 
mL of extraction solvent and centrifuged to remove insoluble materials, and the supernatant was subjected 
to LC-HRMS analysis. 
 
1.6 Analytical methods and equipment overview 
(a) NMR spectroscopy: NMR spectroscopic instrumentation: a Bruker AvanceIII HD (800 MHz 1H reference 
frequency, 201 MHz for 13C) equipped with a 5 mm CPTCL 1H-13C/15N cryo probe. Non-gradient phase-
cycled dqfCOSY spectra were acquired using the following parameters: 0.6 s acquisition time, 400-600 
complex increments, 8, 16 or 32 scans per increment. Non-gradient HSQC, HMQC, and HMBC spectra 
were acquired with these parameters: 0.25 s acquisition time, 200-500 complex increments, 8-64 scans per 
increment. 1H, 13C-HMBC spectra were optimized for JH,C = 6 Hz. HSQC spectra were usually acquired 
without decoupling. NMR spectra were processed and baseline corrected using MestreLabs MNOVA 
software packages. (b) Mass spectrometry: LC-HRMS was performed on a Thermo Scientific-Dionex 
Ultimate3000 UHPLC system equipped with a diode array detector and connected to a Thermo Scientific 
Q-Exactive Orbitrap operated in electrospray positive (ESI+) or electrospray negative (ESI-) ionization mode. 
Low-resolution HPLC-MS was performed on an Agilent 1100 series HPLC system equipped with a diode 
array detector and connected to a Quattro II mass spectrometer (Micromass/Waters) operated in ESI+ or 
ESI- mode. Data acquisition and processing for the LC-HRMS was controlled by Thermo Scientific Xcalibur 
software. Data acquisition and processing for the HPLC-MS was controlled by Waters MassLynx software. 
(c) Chromatography: flash chromatography was performed using a Teledyne ISCO CombiFlash system. For 
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semi-preparative HPLC Agilent Zorbax Eclipse XDB-C18 or -C8 columns (25 cm x 10 mm, 5 μm particle 
diameter) were used. An Agilent Zorbax Eclipse XDB-C18 column (4.6 x 250 mm, 5 μm particle diameter) 
was used in the HPLC-MS analyses of in vitro protein activity assays. For semi-preparative and analytical 
HPLC acetonitrile (organic phase) and 0.1 % acetic acid in water (aqueous phase) were used as solvents 
at a flow rate of 3.20 mL/min or 1.0 mL/min, respectively. A solvent gradient scheme was used, starting at 
5% organic for 3 min, followed by a linear increase to 100% organic over 25 min, holding at 100% organic 
for 8 min, then decreasing back to 5% organic for 1 min and holding at 5% organic for the final 6 min, a total 
of 40 min. An Agilent Zorbax RRHD Eclipse XDB-C18 column (2.1 x 100 mm, 1.8 µm particle diameter) 
heated to 40 C was used in the LC-HRMS A. fumigatus mutant profiling analysis with acetonitrile (organic 
phase) and water (aqueous phase) with 0.1 % acetic acid used as solvents at a flow rate of 0.5 mL/min. For 
data displayed in Figure 2 a solvent gradient scheme was used, starting at 5% organic with an immediate 
linear increase to 100% organic over 10.5 min, holding at 100% organic for 4 min, then decreasing back to 
5% organic in 0.1 min and holding for the final 1.5 min, for a total of 16 min. For data displayed in Figure 4 
a solvent gradient scheme was used, starting at 5% organic for 5 min, then a linear increase to 100% organic 
over 15 min, holding at 100% organic for 5 min, then decreasing back to 5% organic in 0.1 min and holding 
for the final 2.9 min, for a total of 28 min. 
 
1.7 Heterologous protein production 
All C-terminal hexahistidine-tagged GliP mutants, and truncation expression constructs were used to 
transform E. coli BL21(DE3) (New England Biolabs), which was grown in Terrific Broth (TB) supplemented 
with 10 mM MgCl2 and selected with 100 µg/mL ampicillin. 10 mL overnight cultures were diluted into 1 L of 
TB in a 4 L flask and shaken at 200 RPM at 37 °C to an OD of approximately 0.75, cooled to 16 °C and 
further grown to an OD of roughly 1.0-1.2 and induced with 100 µM IPTG. Cultures were maintained at 16 °C 
at 200 RPM for an additional 24 hours before harvesting at 5,000 x g (4 °C for 10 min) and stored at -80 °C 
until purification. All further steps occurred at 4 °C unless otherwise noted. 20 g of frozen pellets were 
resuspended in 150 mL of 25 mM Tris pH 8.0, 500 mM NaCl, and sonicated. Lysed cells were spun at 
20,000 x g for 20 min, and the supernatant was collected and gently stirred with 1 mL HisPur Ni-NTA Resin 
(Thermo Fisher Scientific) for 30 min. During incubation, 5 µL of Benzonase (EMD Millipore) was added 
along with 1 mM MgCl2. The slurry was loaded and passed through a column and the resin was washed 
with 20 column volumes of fresh lysis buffer. The protein was then eluted with 30 mL lysis buffer containing 
150 mM imidazole and 10% glycerol. The elution was concentrated with an Amicon Ultra-15 30 kDa spin 
filter (EMD Millipore), flash frozen over liquid nitrogen and stored at -80 °C until further purification. FPLC 
purification of proteins were performed using a HiLoad 16/600 Superdex 200 preparatory grade column run 
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on a Amersham Biosciences P-920 pump equipped with a UPC-900 detector and a Frac-950 fraction 
collector (GE Healthcare) with a running buffer of 20 mM Tris, pH 8.0, 50 mM NaCl, 2 mM MgCl2, and 1 mM 
DTT. Fractions containing the protein of interest were combined and concentrated with an Amicon Ultra-15 
30 kDa spin filter and flash frozen over liquid nitrogen and stored at -80 °C until further analysis was required. 
 
 
1.8 GliP product formations assays  
GliP assays were first pantetheinylated in 75 mM Tris pH 8.0, 5 mM MgCl2, 300 µM coenzyme A, 1 µM Sfp 
synthase (New England Biolabs), and 1 µM GliP (or GliP mutant) in 100 µL reactions at 25 ºC for 1 hour. 
Following Sfp incubation, an additional 100 µL solution of 10 mM ATP, 800 µM phenylalanine, and 800 µM 







1.9 GliP T3-pantetheine detection 
1 µM GliP in 100 µL was incubated with 75 mM Tris pH 8.0, 5 mM MgCl2, 300 µM coenzyme A, 1 µM Sfp 
synthase at 25 °C. After 1 hour, proteins were digested with 1.5 µg of sequencing grade chymotrypsin 
(Promega) for 12 hours. Peptides were then reduced with 5 mM DTT for 20 minutes at 50 ºC, and thiols 
were capped with 15 mM iodoacetamide. Formic acid was added to 1 % (v/v), and peptides were prepared 
with 100-μl Pierce C18 Tips (Thermo Scientific) per the manufacturer’s protocol using 100 μL of the elution 
solution. Peptides were identified via LC-HRMS, as described above.  
 
 
1.10 Compound 5 cyclization assay 
1 µM GliP_S555A_S1582A in 100 µL was incubated with 50 mM Tris pH 7.5, 5 mM MgCl2, 100 µM 
coenzyme A, 1 µM Sfp synthase at 25 °C for 30 min. Catalysis was initiated with 1 µL of 100 mM 5, and 
after 10 minutes the reaction was quenched with 100 µL acetonitrile and immediately frozen over liquid 
nitrogen. Samples were thawed only immediately before HPLC analysis. Analysis was performed with low-
resolution HPLC-MS, as described above. 
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1.11 ATP-[32P]pyrophosphate exchange assays 
The reactions were set up in a total assay volume of 100 µL at 25 °C in 100 mM phosphate buffer, 5 mM 
MgCl2, 125 nM EDTA, 5 mM ATP, 100 nM purified GliP proteins, 0.1 µM [32P]pyrophosphate (50 Ci/mmol), 
and 1 mM amino acid substrate were added. The reaction proceeded for 30 min before it was stopped (1 % 
(w/v) activated charcoal, 4.5 % (w/v) tetrasodium pyrophosphate, 3.5 % (v/v) perchloric acid) and further 




1.12 Synthesis of N-acetylcystamine-L-Phe-L-Ser (5)  
 
 a) EDC (1.2 eq), HOBt (1.2 eq.), DIEA (3 eq.) DMF, 24 h. b) H2 (continuous stream), Pd/C (10 mol %), 1.5 
h. c) N-acetylcystamine (1.5 eq.), EDC (1.2 eq.), HOBt (1.2 eq.), DIEA (3 eq.) DMF, 24 h. d) 40 % TFA, 




1.13 Mining for putative DKP producing NRPSs with ATCATCTTC domain architecture (Table S1).  
GliP (accession: AAW03307.1) was used as a query sequence for a blastp search of NCBI’s Fungi (taxid: 
4751) non-redundant protein database using the default parameters with a total of 20000 subject sequences. 
The resulting hits were exported to an excel sheet and dereplicated (for multiple alignments to the same 
sequence) and sorted for size (2100-2300 amino acids) to obtain NRPSs with the correct domain 
architecture. The resulting sequences (156) were parsed with Python to search for the conserved residues 
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correct domain architecture and to remove homologs >95 % similarity to GliP, which likely produce gliotoxin. 
The resulting 56 putative NRPSs are annotated in Table S1.  
 
1.14 Gene sequences for GliP-WT and mutant GliP proteins.  
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2 Supporting Figures 
 
 
Figure S1. Amino acid sequence of CTT3 domains of GliP (Af293). Residues highlighted in yellow are 




Figure S2. gliI gene expression in WT(Af293) GliP-CTT3 and GliP-T3 A. fumigatus strains. 107 spores/mL 




Figure S3. Gene expression of gliC, gliG, gliI and gliJ in WT(Af293), GliP, GliI, and GliP-CTT3 A. 
fumigatus strains. 107 spores/mL were inoculated in 50 mL liquid GMM and incubated for 24 h at 30 ºC, 225 
rpm and an additional 24 h at 25ºC, 225 rpm before adding gliotoxin (1, 25 mg/mL). After 24 h of further 
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Figure S4. SDS-PAGE confirmation of recombinant GliP-CTT3, GliP-T3, and GliP-WT.  
 
 
Figure S5. ATP-[32P]PPi- radioisotope exchange assay results for (a) recombinant GliP-WT, (b) GliP-T3, 
and (c) GliP-CTT3. Shown are raw turnover rates for L-Phe, L-Ser, L-His, and water for each enzyme,[14] 
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Figure S6. In vitro product formation assays with GliP. (top) L-Phe and L-Ser incubated with purified GliP 
variants furnishes 2. (bottom) Quantification of relative yield of 2 from each assay, as measured by 




Figure S7. LC-HRMS/MS confirmation of phosphopantetheinyl modification of GliP-T3. See Supporting 
Methods for experimental details.[15]  






Figure S8. In vitro cyclization activity of GliP-T1T2 toward 5. (a) 5 can first be loaded onto T3 via trans-
thiolation, then cyclized by the CT domain to form 2, or (b) the CT domain can directly cyclize 5 to form 2.  
  




Figure S9: Examples for conservation of the CT domain in confirmed and putative DKP producing fungal 
NRPSs. (top) Conserved amino acid sequence in the CT domains are highlighted in red text. Percentages 
are total amino acid similarity. (bottom) Phylogenetic tree for GliP homologs containing CTTC tandem, see 
































































PENFLA_c013G03821 (Penicillium flavigenum) -SHAIADLNS- 61 %
putative NRPS (Bipolaris victoriae FI3) -SHAITDLNS- 47 %
putative NRPS (Trichoderma virens Gv29-8) -SHMIADLNS- 44 %
putative NRPS (Escovopsis weberi) -SHSISDLGT- 39 %
putative NRPS (Leptosphaeria maculans JN3) -SHMIGDRST- 31 %
Aspzo1_0162131 (Aspergillus zonatus) -SHVVGDAAT- 31 %
putative NRPS (Fusarium acenaceum) -SHVVGDAVT- 30 %
NFIA_064400 (Neosartorya fischeri) -SHVVGDAAT- 30 %
ATEG_08427 (Aspergillus terreus) -SHVVADATT- 30 %
TSTA_055660 (Talaromyces stipitatus) -HHIVIDKHS- 30 %
Aspsy1_0160604 (Aspergillus sydowii) -HHIITDKAS- 30 %
TRV_04720 (Trichophyton verrucosum) -SHVVGDATT- 29 %
-SHXXXDXXS/T-







Figure S10: Model for hexadehydroastechrome biosynthesis in Aspergillus fumigatus.  Prenylation of a TC-
tethered dipeptide (as opposed to prenylation of the cyclized DKP) would explain copious production of 






Figure S11: Southern confirmation. (a) A. fumigatus CTT3 and T3 deletion mutants. Genomic DNA was 
digested by NdeI. WT (10 kb), CTT3 deletion (4.7 and 6 kb) and T3 deletion (4.7 and 7.3 kb). TJW139.30 and 
TJW140.16 were chosen for the subsequent experiments. (b) Complementation of CTT3 deletion mutant. 
Genomic DNA was digested by BamHI and HindIII with 3.6 kb fragment expectation. TJW178.26 was 
chosen for subsequent experiment. 
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Figure S12: Confirmation of gliP deletion strain. The GliP open reading frame was replaced with a copy of 
pyrG from A. parasiticus. Genomic DNA was digested by EcoRI; the wildtype (WT) parental control shows 





Figure S13: Confirmation of gliP complementation and cluster expression. (a) Genomic DNA was extracted 
and digested with BamHI; wild-type (WT) parental control shows the expected band of 4.7 kb while all 
transformants show the expected banding pattern of 6.7 and 5.4 kb. (b) Northern analysis of gliG expression 
in wild-type strains (AF293 & TBTP105) as well as gliP (TBTP94), gliP complement strain (TBTP99) and 
the gliP-H1754A point mutant (TBTP100). Strains were grown in liquid GMM for 72 h at 25 °C at 225 RPM.
    








Figure S14: Southern confirmation of S2095A point mutant. Genomic DNA was digested by NdeI. WT (10 
kb), and point mutation (4.7 and 7.5 kb). TJW201.38 was chosen for the subsequent experiments. 
 
3 Supporting Tables 
Table S1. Fungal NRPSs with homologous domain architecture to GliP   
Accession Name Species [%] similarity  
GAQ03188.1 
nonribosomal peptide 
synthetase 10  Aspergillus lentulus 93.192 
XP_024683983.1 
nonribosomal peptide 
synthase GliP  Aspergillus novofumigatus IBT 16806 91.589 
GAO88012.1 
nonribosomal peptide 
synthetase 10  Aspergillus udagawae 88.832 
XP_026610442.1 
hypothetical protein 
CDV56_101444  Aspergillus thermomutatus 87.482 
XP_016603809.1 
AMP-dependent 
synthetase/ligase  Penicillium expansum 60.784 
OQE22222.1 
hypothetical protein 




WT 7  15 28  29  33 34 38 45 94
TJW201.
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ABV48729.1 
non ribosomal peptide 
synthase  Penicillium lilacinoechinulatum 59.605 
RYP29373.1 
hypothetical protein 
DL767_006759  Monosporascus sp. MG133 40.071 
ETR98473.1 
acetyl-CoA synthetase-
like protein  Trichoderma reesei RUT C-30 39.666 
XP_006961011.1 
non-ribosomal peptide 
synthetase, partial  Trichoderma reesei QM6a 39.666 








CI102_1861  Trichoderma harzianum 38.28 
XP_024772669.1 
hypothetical protein 
M431DRAFT_496332  Trichoderma harzianum CBS 226.95 38.28 
XP_024745528.1 
non-ribosomal peptide 
synthetase  Trichoderma citrinoviride 38.279 
XP_018138929.1 
nonribosomal peptide 
synthase GliP2  Pochonia chlamydosporia 170 37.562 
RZR63507.1 
hypothetical protein 
I1G_00004049  Pochonia chlamydosporia 123 37.466 
OAA41296.1 
non-ribosomal peptide 
synthetase  Metarhizium rileyi RCEF 4871 36.233 
XP_022397513.1 
hypothetical protein 
ASPGLDRAFT_51264  Aspergillus glaucus CBS 516.65 31.302 
AAS92545.1 SirP Leptosphaeria maculans 31.2 
XP_022577239.1 
hypothetical protein 
ASPZODRAFT_162131  Penicilliopsis zonata CBS 506.65 30.66 
KGO76902.1 
AMP-dependent 
synthetase/ligase  Penicillium italicum 30.45 
KPA37248.1 
non-ribosomal peptide 
synthetase  Fusarium langsethiae 30.277 
XP_001263173.1 
nonribosomal peptide 
synthase GliP2  Aspergillus fischeri NRRL 181 30.072 
GAO85048.1 
nonribosomal peptide 
synthetase 5  Aspergillus udagawae 30.072 
XP_025480600.1 
putative Nonribosomal 
peptide synthetase 5  Aspergillus neoniger CBS 115656 30.062 
OQE90703.1 
hypothetical protein 
PENNAL_c0011G10486  Penicillium nalgiovense 30 
KEY80879.1 
nonribosomal peptide 
synthase GliP2  Aspergillus fumigatus var. RP-2014 29.991 
OXN05566.1 
hypothetical protein 
CDV58_05250  Aspergillus fumigatus 29.95 
EDP52461.1 
nonribosomal peptide 








Fusarium oxysporum f. sp. lycopersici 
MN25 29.883 




synthetase 5  Fusarium oxysporum f. sp. narcissi 29.883 
GAQ04194.1 
nonribosomal peptide 
synthetase 5  Aspergillus lentulus 29.878 
XP_754329.2 HasD Aspergillus fumigatus Af293 29.86 
EWY87626.1 
hypothetical protein 
FOYG_11806  Fusarium sp. FOSC 3-a 29.835 
EKG15398.1 
AMP-dependent 
synthetase/ligase  Macrophomina phaseolina MS6 29.786 
EWZ34065.1 
hypothetical protein 









Fusarium oxysporum f. sp. radicis-
lycopersici 26381 29.668 
RKK80740.1 
Nonribosomal peptide 
synthetase 5  Fusarium oxysporum 29.668 
XP_020126697.1 
nonribosomal peptide 
synthase 2  Diplodia corticola 29.51 
KIL87746.1 
non-ribosomal peptide 
synthetase  Fusarium avenaceum 29.499 
XP_001217048.1 
hypothetical protein 
ATEG_08427  Aspergillus terreus NIH2624 29.451 
RMJ26839.1 
non-ribosomal peptide 
synthase  Phialosimplex sp. HF37 29.341 
KXG49620.1 
AMP-dependent 
synthetase/ligase  Penicillium griseofulvum 29.328 
OAL68959.1 
hypothetical protein 
A7D00_7126  Trichophyton violaceum 29.255 
DAA76165.1 
TPA_exp: Nonribosomal 
peptide synthase GliP  Trichophyton benhamiae CBS 112371 29.25 
XP_003021172.1 
nonribosomal peptide 
synthase GliP  Trichophyton verrucosum HKI 0517 29.185 
XP_003013751.1 
nonribosomal peptide 
synthase GliP  Trichophyton benhamiae CBS 112371 29.061 
XP_024677137.1 
nonribosomal peptide 
synthase GliP2  Aspergillus novofumigatus IBT 16806 29.04 
EGE05589.1 
nonribosomal peptide 
synthase GliP2  Trichophyton equinum CBS 127.97 28.799 
EZF68370.1 
hypothetical protein 
H104_00006  Trichophyton rubrum CBS 289.86 28.798 
XP_024704292.1 
nonribosomal peptide 
synthase GliP2  Aspergillus steynii IBT 23096 28.444 
KKP03905.1 
hypothetical protein 
THAR02_03993  Trichoderma harzianum 24.906 
OOQ91422.1 
nonribosomal peptide 
synthetase 13  Penicillium brasilianum 24.415 
-NRPSs with >95 % similarity to GliP are excluded from this table, as they likely produce gliotoxin (1).  
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Table S2. LC-HRMS data of reported compounds  
Compound HR-ESI(+/-) 
Observed (m/z) 
Ion Calculated Ion 
Formula 
Calculated m/z Retention 
time [min] 
1 263.1030 [M-S2+H]+ C13H15N2O4+ 263.1032 5.00 
2 235.1080 [M + H]+ C12H15N2O3+ 235.1082 2.30 
3 279.0801 [M-SCH3+H]+ C13H16N2O3S+ 279.0803 3.84 
4 309.0906 [M + H]+ C14H18N2O4S+ 309.0908 5.00 
 
 Table S3. Fungal strains used in this study 
Name Genotype Reference 
Af293 Wild type [20] 
Af293.1 A. fumigatus pyrG1 [20] 
Af293.6 A. fumigatus pyrG1, argB1 [20] 
ARC2 gliP::para pyrG1 [21] 
TJW139.3 C2T3 gliP:: para pyrG1 This study 
TJW140.16 T3 gliP:: para pyrG1 This study 
TJW201.38 GliP2095ser->ala::AfpyrG; pyrG1 This study 
TBTP94.1 pyrG1; gliP::A.p pyrG1; akuA This Study 
TBTP99.1 pyrG1; gliP::A.p pyrG1; gliP::Af. argB::akuA This Study 
TBTP100.6 pyrG1; gliP::A.p pyrG1; gliP-H1754A::Af. argB::akuA This Study 
TFYL44 pyrG-; argB-;  akuA [22] 
TBPT12 pyrG-; argB-; gliP::A.p pyrG;akuA This study 
TBTP94 pyrG-; gliP::A.p pyrG;  akuA This study 
TBTP99 pyrG-; gliP::A.p pyrG; gliP::Af. argB::akuA This study 
TBTP100 pyrG-; gliP::A.p pyrG; gliP H1754A::Af. argB::akuA This study 
TBTP105 akuA::A.p. pyrG; pyrG1 This study 
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Table S4. PCR primer sets used in this study 
Name Sequence (5’-3’) Purpose 




glutapyrGF TGAACCGGTCGCCTCAAACAATGC CTT3 


























gliP 3’-R CTGGAGCAGCTTCCGTGC Deletion 




Ap-pyrG-F CTCATGTTTGACAGCTTATCATCG Deletion 
Ap-pyrG-R CCGAGAGGACTATTCCGAGG Deletion 
YS F TTCGCGTACTGACAGCACAGG Complement 
YS R GCAAGACGGCGAGACTGTTCC Complement 
KU5’-F TATTGCCGTTGGATCTTTGGGG Complement 
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AFU argB fwd GAACGCGGTCTGCATCCAAG Complement 
AFU argB rev TGGTTAGTAACATTCAGACAGTCGGCATGCAGGGACTGA
ACCTGGTGAATCG 
Complement 




AFU argB rev2 AGCATCCATTCTGCGTCTCG Complement 
gliP_S555A_fwd AAGAGCAGCAAGGGCGTTTCCGCCCATGG SDM of gliP-
S555A 
gliP_S555A_rev CCATGGGCGGAAACGCCCTTGCTGCTCTT SDM of gliP-
S555A 



























Ptmt5‘F AGTCATTCAACGCCGTGTTGGC S2095A mutation 









PtmtglutpyrGF CGTCAGGTTCTTTGAACCGGTCGCCTCAAACAATGC S2095A mutation 
gliGF AAAGGTGAGTCGAGTCGACGC Northern probe 
gliGR ATACTCTTTCTCGCCATGGCC  Northern probe 
gliIinF TTCGTTGGCACCGCATGCATGG Northern probe 
gliIinR AGATAGCCGTCCATTTCTGCCC Northern probe 
gliJF AAGAGGTACCTCTGATCGACGG Northern probe 
gliJR TATCCTCGTTCCACACCTCGTCG Northern probe 
gliCF AGTTCTTCCGCAACTCGCACC Northern probe 
gliCR AGCCAGGAATGTGTCATCCCG Northern probe 
 
  
SUPPORTING INFORMATION          
 27 
Table S5. 1H (600 MHz) and 13C (151 MHz) NMR spectroscopic data for compound 5 in a 80:20 mixture of 
methanol-d4 : chloroform-d3. 
Chemical shifts were referenced to δ(CHD2OD) = 3.31 ppm and δ(13CHD2OD) = 49.00.13C chemical shifts 
were determined via HMBC, HSQC and direct observation 13C spectra. 1H, 1H-J-coupling constants were 
determined from the acquired 1H or dqfCOSY spectra. HMBC correlations are from the proton(s) stated to 
the indicated 13C atom. 
 
 
No. δc Proton δH(JHH[Hz]) HMBC 
1 129.28 1-H 7.24 (J1,2 = 7.5) 3 
2 127.68 2-H2 7.21 (J2,1 = 7.5) (J2,3 = 7.4) 2,4 
3 128.92 3-H2 7.25 (J3,2 = 7.4) (J3,5 = 1.0) 1,3,5 
4 133.65    
5 36.87 5-Ha 2.98 (J5a,5b = 14.0) (J5a,6 = 8.2) (J5a,3 = 1.0) 3,4,6,7 
5-Hb 3.28 (J5b,5a = 14.0) (J5b,6 = 5.5) (J5a,3 = 1.0) 3,4,6,7 
6 54.39 6-H 4.26 (J6,5a = 8.2) (J6,5a = 5.5) 4,5,7 
7 168.86    
8  8-NH    
9 61.54 9-H 4.55 (J9,10a = 4.0) (J9,10b = 4.5) 7,10,11 
10 61.70 10-Ha 3.75 (J10a,10b = 11.8) (J10a,9 = 4.0) 9,11 
10-Hb 3.84 (J10b,10a = 11.8) (J10b,9 = 4.5) 9,11 
11 198.19    
12     
13 28.44 13-H2 2.90 (J13,14 = 12.0) 11,14 
14 38.48 15-H2 3.27 (J14,13 = 12.0) 13,16 
15  15-NH   
16 172.01    
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